SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment

Literature

• Hochhaus A, La Rosee P, Eigendorff E, et al. Chronic myelogenous leukemia. Internist. 2015;56(4):333–343.
   PubMed Web of Science ®Google Scholar
• Burchert A, Neubauer A. Chronic myeloid leukemia. Diagnostics, therapy and future strategy. Internist. 2011;52(3):283–293.
   PubMedGoogle Scholar
• Heisterkamp N, Groffen J, Stephenson JR, et al. Chromosomal localization of human cellular homologues of two viral oncogenes [research support, U.S. Gov’t, P.H.S.]. Nature. 1982;299(5885):747–749.
   PubMed Web of Science ®Google Scholar
• de Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia [research support, Non-U.S. Gov’t research support, U.S. Gov’t, P.H.S.]. Nature. 1982;300(5894):765–767.
   PubMed Web of Science ®Google Scholar
• Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 [research support, Non-U.S. Gov’t research support, U.S. Gov’t, P.H.S.]. Cell. 1984;36(1):93–99.
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing committee for the collaborative CML prognostic factors project group. J Natl Cancer Inst. 1998;90(11):850–858.
   PubMedGoogle Scholar
• Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686–692.
   PubMed Web of Science ®Google Scholar
• Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48–56.
   PubMed Web of Science ®Google Scholar
• Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling [research support, Non-U.S. Gov’t research support, U.S. Gov’t, P.H.S.]. Nature. 1997;387(6636):917–921.
   PubMed Web of Science ®Google Scholar
• Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases [research support, Non-U.S. Gov’t]. Nature. 1997;387(6636):921–924.
   PubMed Web of Science ®Google Scholar
• Kim WS, Kim MJ, Kim DO, et al. Suppressor of cytokine signaling 2 negatively regulates NK cell differentiation by inhibiting JAK2 activity. Sci Rep. 2017;7:46153.
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Bhattacharya S, Braunstein J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285(1–2):1–24.
   PubMed Web of Science ®Google Scholar
• Zhang JG, Farley A, Nicholson SE, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation [research support, Non-U.S. Gov’t research support, U.S. Gov’t, P.H.S.]. PNAS. 1999;96(5):2071–2076.
   PubMed Web of Science ®Google Scholar
• Ram PA, Waxman DJ. Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone [research support, U.S. Gov’t, P.H.S.]. J Biol Chem. 2000;275(50):39487–39496.
   PubMed Web of Science ®Google Scholar
• Dogusan Z, Hooghe-Peters EL, Berus D, et al. Expression of SOCS genes in normal and leukemic human leukocytes stimulated by prolactin, growth hormone and cytokines. J Neuroimmunol. 2000;109(1):34–39.
   PubMed Web of Science ®Google Scholar
• Faderl S, Harris D, Van Q, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood. 2003;102(2):630–637.
   PubMed Web of Science ®Google Scholar
• Greenhalgh CJ, Bertolino P, Asa SL, et al. Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b) [research support, Non-U.S. Gov’t research support, U.S. Gov’t, P.H.S.]. Mol Endocrinol. 2002;16(6):1394–1406.
   PubMedGoogle Scholar
• Greenhalgh CJ, Metcalf D, Thaus AL, et al. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem. 2002;277(43):40181–40184.
   PubMed Web of Science ®Google Scholar
• Zheng C, Li L, Haak M, et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia. 2006;20(6):1028–1034.
   PubMed Web of Science ®Google Scholar
• Schultheis B, Carapeti-Marootian M, Hochhaus A, et al. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism [research support, Non-U.S. Gov’t]. Blood. 2002;99(5):1766–1775.
   PubMed Web of Science ®Google Scholar
• Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. PNAS. 2006;103(8):2794–2799.
   PubMed Web of Science ®Google Scholar
• Vitali C, Bassani C, Chiodoni C, et al. SOCS2 controls proliferation and stemness of hematopoietic cells under stress conditions and its deregulation marks unfavorable acute leukemias. Cancer Res. 2015;75(11):2387–2399.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Ng SY, Zuniga-Pflucker JC, et al. Early hematopoietic lineage restrictions directed by ikaros. Nat Immunol. 2006;7(4):382–391.
   PubMed Web of Science ®Google Scholar
• Yagi T, Hibi S, Takanashi M, et al. High frequency of Ikaros isoform 6 expression in acute myelomonocytic and monocytic leukemias: implications for up-regulation of the antiapoptotic protein Bcl-XL in leukemogenesis. Blood. 2002;99(4):1350–1355.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood. 2008;112(9):3847–3855.
   PubMed Web of Science ®Google Scholar
• Nakayama H, Ishimaru F, Avitahl N, et al. Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia. Cancer Res. 1999;59(16):3931–3934.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61(7):1441–1446.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32(5):415–423.
   PubMed Web of Science ®Google Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156–159.
   PubMed Web of Science ®Google Scholar
• Qiagen. Products. Available from: https://www.qiagen.com/de/products/
   Google Scholar
• Horita M, Andreu EJ, Benito A, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000;191(6):977–984.
   PubMed Web of Science ®Google Scholar
• Hantschel O, Warsch W, Eckelhart E, et al. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol. 2012;8(3):285–293.
   PubMed Web of Science ®Google Scholar
• Sen B, Peng S, Woods DM, et al. STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res. 2012;18(1):127–139.
   PubMed Web of Science ®Google Scholar
• Coppo P, Flamant S, De Mas V, et al. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol. 2006;134(2):171–179.
   PubMed Web of Science ®Google Scholar
• Sillaber C, Gesbert F, Frank DA, et al. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000;95(6):2118–2125.
   PubMed Web of Science ®Google Scholar
• Hoelbl A, Schuster C, Kovacic B, et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med. 2010;2(3):98–110.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Ray RM, Johnson LR. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J. 2005;392(Pt 2):335–344.
   PubMed Web of Science ®Google Scholar
• Cuevas P, Diaz-Gonzalez D, Sanchez I, et al. Dobesilate inhibits the activation of signal transducer and activator of transcription 3, and the expression of cyclin D1 and bcl-XL in glioma cells. Neurol Res. 2006;28(2):127–130.
   PubMed Web of Science ®Google Scholar
• Ilaria RL Jr., Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271(49):31704–31710.
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Ries RE, Gudgeon CJ, et al. High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. Leuk Lymphoma. 2014;55(12):2817–2821.
   PubMed Web of Science ®Google Scholar
• Reynaud D, Pietras E, Barry-Holson K, et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development [research support, N.I.H., extramural research support, Non-U.S. Gov’t]. Cancer Cell. 2011;20(5):661–673.
   PubMed Web of Science ®Google Scholar
• Li Y, Qi X, Liu B, et al. The STAT5-GATA2 pathway is critical in basophil and mast cell differentiation and maintenance. J Immunol. 2015;194(9):4328–4338.
   PubMed Web of Science ®Google Scholar